Antibody Drug Conjugates (ADC) Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2024-2028

Published: Nov 2023 Pages: 156 SKU: IRTNTR76877

Antibody Drug Conjugates (ADC) Market Forecast 2024-2028

The Antibody Drug Conjugates (ADC) Market size is estimated to grow by USD 9.95 billion at a CAGR of 15.06% between 2023 and 2028. The rapid expansion of Antibody-Drug Conjugates (ADCs) in North America propels growth in the Antibody Drug Conjugates Market. ADCs, which merge cytotoxic drugs with monoclonal antibodies to selectively attack tumor cells, dominate due to North America's robust pharmaceutical firms, healthcare infrastructure, and favorable reimbursement policies. The US leads with advanced facilities and high cancer prevalence.

Anticipated growth is fueled by rising cancer rates, biopharmaceutical investments, and research. Techniques like Polymer-drug conjugation and T-cell dual affinity re-targeting are promising in ADC development. Challenges like development costs and toxicity persist. Adoption of targeted therapies, including Prodrugs and Chemotherapy, shapes market growth, impacting ADC market positively. With focus on Monoclonal antibody, Immunotherapy, and Angiogenesis inhibitors, the market expands amidst increasing demand for effective treatments targeting Tumour cells and Antigens.

What will be the Size of the Antibody Drug Conjugates Market During the Forecast Period?

To learn more about this report, Request Free Sample

Antibody Drug Conjugates Market Segmentation by Application, Technology, and Geography Analysis

Application Analysis

Breast cancer

The breast cancer segment is estimated to witness significant growth during the forecast period. This segment is one that is both significant and expanding quickly within the global antibody drug conjugates (ADC) market. ADCs refer to a class of targeted cancer therapy that combines the cytotoxic qualities of chemotherapeutic medicines with the specificity of monoclonal antibodies.

Get a glance at the market contribution of various segments Download PDF Sample

The breast cancer segment was the largest segment and was valued at USD 3.22 billion in 2018. Moreover, breast cancer is one of the most prevalent cancers worldwide, especially in women. In addition, it is linked to a high rate of morbidity and is responsible for a sizable portion of cancer-related fatalities. Therefore, it is crucial to establish efficient and focused breast cancer therapy choices. Furthermore, ADCs provide a viable alternative for treating breast cancer as they target cancer cells specifically and deliver cytotoxic medicines straight to the tumor site. In addition, this targeted delivery reduces the potential side effects associated with traditional chemotherapy, such as damage to healthy cells and tissues. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.

Technology Analysis

Cleavable linker

The cleavable linker segment is a major component of the global antibody drug conjugates market. In addition, ADCs are a brand-new family of targeted therapeutic agents that combine small-molecule medicinal potency with the specificity of monoclonal antibodies (MAbs). Moreover, the ability to selectively release the drug inside the intended cancer cell is made possible by the cleavable linker, which connects the cytotoxic payload (drug) and the antibody. In addition, the cleavable linker is intended to cleave effectively and selectively in the target cell to enable successful drug delivery, but it should also be stable in circulation to prevent premature drug release. .Furthermore, advanced cleavable linkers are witnessing increasing demand as ADC development moves forward. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 50% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The antibody drug conjugates (ADCs) market is expanding quickly in North America due to the factors such as the presence of a significant number of pharmaceutical companies, a well-established healthcare infrastructure, and advantageous reimbursement policies. In addition, ADCs are a family of targeted cancer medicines that combine cytotoxic drugs that kill cancer cells with monoclonal antibodies, which target particular cancer cells. Moreover, due to its modern healthcare facilities and the high prevalence of cancer, the US accounts for the biggest market share in North America. The region's rising cancer incidence rate, increased investments in the biopharmaceutical industry, and an increase in research and development efforts are driving the market growth in North America during the forecast period.

Buy Full Report Now

Market Dynamics and Customer Landscape

The Antibody Drug Conjugates (ADCs) Market, driven by Conjugation techniques like Protein-drug conjugation and Polymer-drug conjugation, offers promising Prodrugs combining cytotoxic Drugs with Monoclonal Antibodies. Polymers, Lipids, and Polypeptides play critical roles in ADC development. T-cell dual affinity re-targeting conjugation enhances specificity. Pharmacokinetics of ADCs, including Payload and Linker stability, impact efficacy.

Biopharmaceutical drugs like Chemotherapy, Antibodies, and Immune system modulators target Surface Antigens on Tumour cells. Angiogenesis inhibitors and Multi-specific Antibodies Therapy further refine treatment. Despite challenges such as high development costs, ADCs continue to revolutionize Immunotherapy, driving market growth.

Key Market Drivers

The market is driven by the rapid expansion of Antibody-Drug Conjugates (ADCs) in North America. ADCs, a class of targeted cancer therapies, blend cytotoxic drugs with monoclonal antibodies to selectively attack tumor cells. North America holds a dominant position globally due to numerous pharmaceutical firms, robust healthcare infrastructure, and favorable reimbursement policies. The US leads in market share, buoyed by advanced healthcare facilities and high cancer prevalence. Anticipated growth in the coming years is propelled by rising cancer rates, increased biopharmaceutical investments, and heightened research efforts.

Major pharmaceutical players like Pfizer Inc. and F. Hoffmann La Roche Ltd. dominate the competitive landscape through strategic partnerships. Polymer-drug conjugation and T-cell dual affinity re-targeting conjugation are emerging as promising techniques in ADC development. Despite bright prospects, challenges such as development costs, stringent regulations, and potential toxicity persist. The COVID-19 pandemic initially disrupted ADC supply chains but rebounded with governmental vaccination drives, underscoring the market's resilience amidst challenges.

With cancer cases soaring, the demand for effective treatments ensures continued market growth. Notable ADCs include ado-trastuzumab emtansine (Kadcyla), inotuzumab ozogamicin (Besponsa), gemtuzumab ozogamicin (Mylotarg), polatuzumab vedotin-piiq (Polivy), enfortumab vedotin (Padcev), sacituzumab govitecan (Trodelvy), trastuzumab deruxtecan (Enhertu), belantamab mafodotin-blmf (Blenrep), mirvetuximab soravtansine (Elahere), tisotumab vedotin (Tivdak), cetuximab sarotalocan (Akalux), disitamab vedotin (Aidixi), and loncastuximab tesirine-lpyl (Zynlonta). Pharmacokinetics and angiogenesis inhibitors play crucial roles in enhancing ADC efficacy. The development of tumor antigen-specific antibodies and anti-HER2 medications like valine citrulline (VC) showcases ongoing advancements in the field.

Significant  Market Trends

A key factor shaping the antibody drug conjugates market growth is the increasing adoption and development of targeted therapies. There has been an increasing acceptance and development of targeted therapies, which is a notable trend in the global antibody drug conjugates market. In addition,  ADCs, or antibody drug conjugates, are a family of biopharmaceutical medications that target cancer cells specifically with deadly chemicals by using monoclonal antibodies.

Moreover, pharmaceutical firms and medical experts are taking notice of these innovative drugs as they appear to be effective in treating a variety of cancers. In addition, growing knowledge of the underlying molecular pathways of cancer progression is one of the key drivers propelling the use of targeted therapies. Hence, such factors are positively impacting the antibody drug conjugates (ADC) market. Therefore, it is expected to drive the market growth during the forecast period.

Major Challenges

High development costs for antibody drug conjugates are one of the key challenges hindering the antibody drug conjugates market growth. The global antibody drug conjugates market is facing high development costs, which poses a major challenge to market growth. In addition, ADCs are a class of targeted cancer therapies that combine the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapy drugs.

Moreover, developing and manufacturing ADCs involves multiple complex processes, making it a costly endeavor. For instance, it takes a lot of research and development to create an ADC, including choosing appropriate targets, creating the antibody, and attaching it to the cytotoxic agent. Hence, such factors are negatively impacting the market. Therefore, it is expected to hinder the market growth during the forecast period.

Buy Now Full Report

Key Antibody Drug Conjugates Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Antibody Drug Conjugates Market Customer Landscape

Market Analyst Overview

The Antibody Drug Conjugates (ADCs) market is witnessing significant advancements in conjugation technology, integrating prodrugs, polypeptides, lipids, polymers, and carbohydrates with therapeutic proteins. This innovative approach, including protein-drug conjugation and antibody-drug conjugation, has revolutionized biopharmaceutical drugs, particularly in immunotherapy.

By targeting surface antigens on tumor cells, ADCs deliver potent anti-cancer agents directly to the site of action, minimizing off-target effects. Notable examples include Kadcyla, Enhertu, and Adcetris, which employ chemical linkers to attach cytotoxic payloads like MMAE and DM4 to monoclonal antibodies such as trastuzumab and brentuximab vedotin (Adcetris).

These advancements extend to multi-specific antibodies therapy, combining anti-angiogenic agents and DNA damage response agents to enhance efficacy. Moreover, ADCs like Padcev and Trodelvy demonstrate promising outcomes in targeting PD-L1 and MHC molecules, bolstering the immune system response against cancer.

As market research and growth projects a robust trajectory for ADCs, including market growth and forecasting and market forecasting, ongoing developments in bioconjugation techniques and the introduction of novel agents like Polivy and Tivdak are poised to further drive the market forward.

Segment Overview

The antibody drug conjugates market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

  • Application Outlook
    • Breast cancer
    • Blood cancer
    • Others
  • Technology Outlook
    • Cleavable linker
    • Non-cleavable linker
    • Linkerless
  • Geography Outlook
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of the World (ROW)
      • Australia
      • Argentina
      • Brazil

Antibody Drug Conjugates Market Scope

Report Coverage

Details

Page number

156

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 15.06%

Market Growth 2024-2028

USD 9.95 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

14.35

Regional analysis

North America, Europe, Asia, and the Rest of the World (ROW)

Performing market contribution

North America at 50%

Key countries

US, Germany, UK, China, and Japan

Competitive landscape

 Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., Adcendo ApS, Araris Biotech AG, Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., ImmunoGen Inc., Merck KGaA, Mersana Therapeutics Inc., Mythic Therapeutics, Pfizer Inc., Piramal Enterprises Ltd., PPF Group, Regeneron Pharmaceuticals Inc., Seagen Inc., Syngene International Ltd., Takeda Pharmaceutical Co. Ltd., and ADC Therapeutics SA

Market dynamics

Parent market analysis, Market growth analysis and inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Antibody Drug Conjugates Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the antibody drug conjugates market between 2024 and 2028
  • Precise estimation of the antibody drug conjugates market size and its contribution to the market in focus on the parent market
  • Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
  • Companies landscape comparing criticality of inputs and factors of differentiation
  • Exclusive Matrix on companies position and classification
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market across North America, Europe, Asia, and the Rest of the World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the growth of antibody drug conjugates market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Technology
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global antibody drug conjugates market 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on global antibody drug conjugates market 2018 - 2022 ($ billion)
    • 4.2 Application Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – Application Segment 2018 - 2022 ($ billion)
    • 4.3 Technnology Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – Technnology Segment 2018 - 2022 ($ billion)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Application

    • 6.1 Market segments
      • Exhibit 30: Chart on Application - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on Application - Market share 2023-2028 (%)
    • 6.2 Comparison by Application
      • Exhibit 32: Chart on Comparison by Application
      • Exhibit 33: Data Table on Comparison by Application
    • 6.3 Breast cancer - Market size and forecast 2023-2028
      • Exhibit 34: Chart on Breast cancer - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 35: Data Table on Breast cancer - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 36: Chart on Breast cancer - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on Breast cancer - Year-over-year growth 2023-2028 (%)
    • 6.4 Blood cancer - Market size and forecast 2023-2028
      • Exhibit 38: Chart on Blood cancer - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 39: Data Table on Blood cancer - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 40: Chart on Blood cancer - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on Blood cancer - Year-over-year growth 2023-2028 (%)
    • 6.5 Others - Market size and forecast 2023-2028
      • Exhibit 42: Chart on Others - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 43: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 44: Chart on Others - Year-over-year growth 2023-2028 (%)
      • Exhibit 45: Data Table on Others - Year-over-year growth 2023-2028 (%)
    • 6.6 Market opportunity by Application
      • Exhibit 46: Market opportunity by Application ($ billion)
      • Exhibit 47: Data Table on Market opportunity by Application ($ billion)

    7 Market Segmentation by Technology

    • 7.1 Market segments
      • Exhibit 48: Chart on Technology - Market share 2023-2028 (%)
      • Exhibit 49: Data Table on Technology - Market share 2023-2028 (%)
    • 7.2 Comparison by Technology
      • Exhibit 50: Chart on Comparison by Technology
      • Exhibit 51: Data Table on Comparison by Technology
    • 7.3 Cleavable linker - Market size and forecast 2023-2028
      • Exhibit 52: Chart on Cleavable linker - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 53: Data Table on Cleavable linker - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 54: Chart on Cleavable linker - Year-over-year growth 2023-2028 (%)
      • Exhibit 55: Data Table on Cleavable linker - Year-over-year growth 2023-2028 (%)
    • 7.4 Non-cleavable linker - Market size and forecast 2023-2028
      • Exhibit 56: Chart on Non-cleavable linker - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 57: Data Table on Non-cleavable linker - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 58: Chart on Non-cleavable linker - Year-over-year growth 2023-2028 (%)
      • Exhibit 59: Data Table on Non-cleavable linker - Year-over-year growth 2023-2028 (%)
    • 7.5 Linkerless - Market size and forecast 2023-2028
      • Exhibit 60: Chart on Linkerless - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 61: Data Table on Linkerless - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 62: Chart on Linkerless - Year-over-year growth 2023-2028 (%)
      • Exhibit 63: Data Table on Linkerless - Year-over-year growth 2023-2028 (%)
    • 7.6 Market opportunity by Technology
      • Exhibit 64: Market opportunity by Technology ($ billion)
      • Exhibit 65: Data Table on Market opportunity by Technology ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 67: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 68: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 69: Chart on Geographic comparison
      • Exhibit 70: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 Germany - Market size and forecast 2023-2028
      • Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.9 China - Market size and forecast 2023-2028
      • Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)
    • 9.10 UK - Market size and forecast 2023-2028
      • Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.11 Japan - Market size and forecast 2023-2028
      • Exhibit 103: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 104: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 105: Chart on Japan - Year-over-year growth 2023-2028 (%)
      • Exhibit 106: Data Table on Japan - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 107: Market opportunity by geography ($ billion)
      • Exhibit 108: Data Tables on Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 109: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 111: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 112: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 113: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 114: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Exhibit 115: AbbVie Inc. - Overview
              • Exhibit 116: AbbVie Inc. - Product / Service
              • Exhibit 117: AbbVie Inc. - Key news
              • Exhibit 118: AbbVie Inc. - Key offerings
            • 12.4 ADC Therapeutics SA
              • Exhibit 119: ADC Therapeutics SA - Overview
              • Exhibit 120: ADC Therapeutics SA - Product / Service
              • Exhibit 121: ADC Therapeutics SA - Key offerings
            • 12.5 Astellas Pharma Inc.
              • Exhibit 122: Astellas Pharma Inc. - Overview
              • Exhibit 123: Astellas Pharma Inc. - Product / Service
              • Exhibit 124: Astellas Pharma Inc. - Key news
              • Exhibit 125: Astellas Pharma Inc. - Key offerings
            • 12.6 AstraZeneca Plc
              • Exhibit 126: AstraZeneca Plc - Overview
              • Exhibit 127: AstraZeneca Plc - Product / Service
              • Exhibit 128: AstraZeneca Plc - Key news
              • Exhibit 129: AstraZeneca Plc - Key offerings
            • 12.7 Daiichi Sankyo Co. Ltd.
              • Exhibit 130: Daiichi Sankyo Co. Ltd. - Overview
              • Exhibit 131: Daiichi Sankyo Co. Ltd. - Product / Service
              • Exhibit 132: Daiichi Sankyo Co. Ltd. - Key news
              • Exhibit 133: Daiichi Sankyo Co. Ltd. - Key offerings
            • 12.8 F. Hoffmann La Roche Ltd.
              • Exhibit 134: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 135: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 136: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 137: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 138: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.9 Gilead Sciences Inc.
              • Exhibit 139: Gilead Sciences Inc. - Overview
              • Exhibit 140: Gilead Sciences Inc. - Product / Service
              • Exhibit 141: Gilead Sciences Inc. - Key news
              • Exhibit 142: Gilead Sciences Inc. - Key offerings
            • 12.10 ImmunoGen Inc.
              • Exhibit 143: ImmunoGen Inc. - Overview
              • Exhibit 144: ImmunoGen Inc. - Product / Service
              • Exhibit 145: ImmunoGen Inc. - Key offerings
            • 12.11 Merck KGaA
              • Exhibit 146: Merck KGaA - Overview
              • Exhibit 147: Merck KGaA - Business segments
              • Exhibit 148: Merck KGaA - Key news
              • Exhibit 149: Merck KGaA - Key offerings
              • Exhibit 150: Merck KGaA - Segment focus
            • 12.12 Mersana Therapeutics Inc.
              • Exhibit 151: Mersana Therapeutics Inc. - Overview
              • Exhibit 152: Mersana Therapeutics Inc. - Product / Service
              • Exhibit 153: Mersana Therapeutics Inc. - Key offerings
            • 12.13 Pfizer Inc.
              • Exhibit 154: Pfizer Inc. - Overview
              • Exhibit 155: Pfizer Inc. - Product / Service
              • Exhibit 156: Pfizer Inc. - Key news
              • Exhibit 157: Pfizer Inc. - Key offerings
            • 12.14 Regeneron Pharmaceuticals Inc.
              • Exhibit 158: Regeneron Pharmaceuticals Inc. - Overview
              • Exhibit 159: Regeneron Pharmaceuticals Inc. - Product / Service
              • Exhibit 160: Regeneron Pharmaceuticals Inc. - Key offerings
            • 12.15 Seagen Inc.
              • Exhibit 161: Seagen Inc. - Overview
              • Exhibit 162: Seagen Inc. - Key offerings
            • 12.16 Syngene International Ltd.
              • Exhibit 163: Syngene International Ltd. - Overview
              • Exhibit 164: Syngene International Ltd. - Product / Service
              • Exhibit 165: Syngene International Ltd. - Key offerings
            • 12.17 Takeda Pharmaceutical Co. Ltd.
              • Exhibit 166: Takeda Pharmaceutical Co. Ltd. - Overview
              • Exhibit 167: Takeda Pharmaceutical Co. Ltd. - Product / Service
              • Exhibit 168: Takeda Pharmaceutical Co. Ltd. - Key news
              • Exhibit 169: Takeda Pharmaceutical Co. Ltd. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 170: Inclusions checklist
                • Exhibit 171: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 172: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 173: Research methodology
                • Exhibit 174: Validation techniques employed for market sizing
                • Exhibit 175: Information sources
              • 13.5 List of abbreviations
                • Exhibit 176: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              antibody drug conjugates market market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis